Oncopeptides

Oncopeptides is a pharmaceutical company that develops and commercializes therapies for the treatment of hematological cancer. Read more

Marty J Duvall's photo - CEO of Oncopeptides

CEO

Marty J Duvall

CEO Approval Rating

90/100

Founded:

2000

Status:

PublicIndependent CompanyNasdaq OMX NordicONCO

ONCOPEPTIDES TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Cellectis is a top competitor of Oncopeptides. Cellectis was founded in 1999, and is headquartered in New York, New York. Cellectis is in the Biotechnology industry. Cellectis generates $82.5M more revenue vs. Oncopeptides.

OncoImmune is seen as one of Oncopeptides's top competitors. OncoImmune is headquartered in Rockville, Maryland, and was founded in 2000. Like Oncopeptides, OncoImmune also competes in the Pharmaceuticals field. OncoImmune generates ∞% the revenue of Oncopeptides.

Amphivena has been one of Oncopeptides's top competitors. Amphivena's headquarters is in San Francisco, California, and was founded in 2012. Like Oncopeptides, Amphivena also operates in the Pharmaceuticals field. Amphivena generates ∞% of Oncopeptides's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Oncopeptides?

Oncopeptides Quarterly and Annual Revenue

Coming soon for Oncopeptides!

Annual Revenue

Oncopeptides Acquisitions

No recent acquisitions found related to Oncopeptides

Oncopeptides Funding History

Since Oncopeptides was founded in 2000, it has participated in 1 round of funding. In total Oncopeptides has raised $47.1M. Oncopeptides' funding round was on Oct 2020 for a total of $47.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Oct 2020
$47.1M

European Investment Bank

Since Oncopeptides was founded in 2000, it has participated in 1 round of funding. In total Oncopeptides has raised $47.1M. Oncopeptides' funding round was on Oct 2020 for a total of $47.1M

Oncopeptides Investments

No recent investments found related to Oncopeptides

Oncopeptides News

May 17, 2021Markets Insider

Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch

PLEASANTON, Calif., May 17, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a strateg... See more »
May 12, 2021FinanzNachrichten

Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting

STOCKHOLM, May 12, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global bio... See more »
May 5, 2021Drug Delivery Business

Oncopeptides completes enrollment in Phase 2 multiple myeloma study

Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its m... See more »
April 26, 2021BioSpace

Oncopeptides publishes the 2020 Annual Report

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development ... See more »
April 26, 2021BioSpace

Annual General Meeting in Oncopeptides AB (publ) - Apr 26, 2021

The shareholders in Oncopeptides AB, reg. no. 556596-6438, with registered office in the municipality... See more »
April 17, 2021Pharmabiz

Oncopeptides seeks European marketing approval for melflufen to treat r/r multiple myeloma

Oncopeptides, a global biotech company, announced that the company has submitted an application to th... See more »
April 16, 2021Drug Delivery Business

Oncopeptides seeks EU marketing authorization for multiple myeloma treatment

Oncopeptides announced today that it submitted an application for European marketing authorization of... See more »

Oncopeptides Press Releases

October 2, 2020EIN Presswire

Lazarex Cancer Foundation and Oncopeptides Partner to Remove Financial Barriers to Oncopeptides' sEAPort Expanded Access

This Marks the First Innovative Partnership between Lazarex and a Pharmaceutical Company for this Pur... See more »
September 4, 2020StreetInsider

Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announ... See more »
June 15, 2020Cision

Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients

STOCKHOLM - June 15, 2020 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the full... See more »
March 24, 2020centralcharts

The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1)

The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Stud... See more »
September 24, 2019centralcharts

Exercise of Options and Sale of Shares Under the Employee Stock Option Program 2012/2019

Exercise of Options and Sale of Shares Under the Employee Stock Option Program 2012/2019 PR Newswire ... See more »
September 11, 2019PR Newswire

Data From Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

STOCKHOLM, Sept. 11, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today th... See more »

Social Media

Oncopeptides Headquarters

Luntmakargatan 46 Floor 7

Stockholm, Stockholms län111 37

46-8-615-20-40

Driving Directions »

Trending Companies

Oncopeptides Summary

ABOUT

Overview

Oncopeptides is a pharmaceutical company that develops and commercializes therapies for the treatment of hematological cancer. Oncopeptides was founded in 2000. Oncopeptides' headquarters is located in Stockholm, Stockholms län, SE 111 37. It has rais...

CEO

Oncopeptides's CEO, Marty J Duvall, currently has an approval rating of 90%. Oncopeptides's primary competitors are Cellectis, OncoImmune & Amphivena.

Frequently Asked Questions about Oncopeptides

  1. When was Oncopeptides founded?

    Oncopeptides was founded in 2000
  2. Who is Oncopeptides's CEO?

    Oncopeptides's CEO is Marty J Duvall
  3. How much revenue does Oncopeptides generate?

    Oncopeptides generates $ < 1M in revenue
  4. How much funding does Oncopeptides have?

    Oncopeptides has historically raised $47.1M in funding
  1. Where is Oncopeptides's headquarters?

    Oncopeptides's headquarters is in Stockholm Stockholms län, SE
  2. How many employees does Oncopeptides have?

    Oncopeptides has 88 employees
  3. What sector does Oncopeptides operate in?

    Oncopeptides is in Pharmaceuticals
  4. Who are Oncopeptides's competitors?

    Oncopeptides's top competitors are Cellectis, OncoImmune, Amphivena